

**Policy: MP259**

**Section: Medical Benefit Policy**

**Subject: Phototherapy for the Treatment of Dermatological Conditions**

**I. Policy:** Phototherapy for the Treatment of Dermatological Conditions

**II. Purpose/Objective:**

To provide a policy of coverage regarding Phototherapy for the Treatment of Dermatological Conditions

**III. Responsibility:**

- A. Medical Directors
- B. Medical Management

**IV. Required Definitions**

1. Attachment – a supporting document that is developed and maintained by the policy writer or department requiring/authoring the policy.
2. Exhibit – a supporting document developed and maintained in a department other than the department requiring/authoring the policy.
3. Devised – the date the policy was implemented.
4. Revised – the date of every revision to the policy, including typographical and grammatical changes.
5. Reviewed – the date documenting the annual review if the policy has no revisions necessary.

**V. Additional Definitions**

Medical Necessity or Medically Necessary means Covered Services rendered by a Health Care Provider that the Plan determines are:

- a. appropriate for the symptoms and diagnosis or treatment of the Member's condition, illness, disease or injury;
- b. provided for the diagnosis, and the direct care and treatment of the Member's condition, illness disease or injury;
- c. in accordance with current standards of good medical treatment practiced by the general medical community.
- d. not primarily for the convenience of the Member, or the Member's Health Care Provider; and
- e. the most appropriate source or level of service that can safely be provided to the Member. When applied to hospitalization, this further means that the Member requires acute care as an inpatient due to the nature of the services rendered or the Member's condition, and the Member cannot receive safe or adequate care as an outpatient.

**Medicaid Business Segment**

Medical Necessity shall mean a service or benefit that is compensable under the Medical Assistance Program and if it meets any one of the following standards:

- (i) The service or benefit will, or is reasonably expected to, prevent the onset of an illness, condition or disability.
- (ii) The service or benefit will, or is reasonably expected to, reduce or ameliorate the physical, mental or development effects of an illness, condition, injury or disability.
- (iii) The service or benefit will assist the Member to achieve or maintain maximum functional capacity in performing daily activities, taking into account both the functional capacity of the Member and those functional capacities that are appropriate for members of the same age.

**ALL Durable Medical Equipment** provided for home use requires advanced determination of coverage. Devices furnished at inpatient or outpatient centers are **NOT SEPARATELY REIMBURSABLE.**

**DESCRIPTION:**

Phototherapy is defined as the exposure to Ultraviolet radiation for the therapeutic use of skin conditions. The various therapies include Psoralen with Ultraviolet A (PUVA), Ultraviolet A or B, laser UVB, an UVB plus coal tar (Goeckerman regimen). UV therapies reduce inflammation, slow the production of skin cells, and confer an immune-modifying response.

**INDICATIONS:**

The following treatments are considered medically necessary when prescribed by a Dermatologist and any of the following criteria are met:

1. PUVA for the following conditions that are resistant to or not responsive to conventional therapies:

- severe, disabling psoriasis (affecting 10% or more of the body)
- severe dermatitis/ eczema
- Stage IA- IIA Cutaneous T-cell lymphoma (mycosis fungoides)
- Severe Lichen planus
- Cutaneous graft versus host disease
- Sezary's syndrome
- Morphea

2. Laser UVB (Excimer or pulsed dye) is considered medically necessary for mild to moderate psoriasis affecting 10% or less of the body surface area in insured individuals who have had suboptimal response to conservative treatment including topical agents and UV phototherapy, or a contraindication to such treatments.

3. UVA / UVB treatment is medically necessary for the following diseases that is not responsive to conservative therapies:

- psoriasis
- cutaneous T-cell lymphoma (e.g., mycosis fungoides)
- connective tissue diseases involving the skin (e.g., localized scleroderma)
- atopic dermatitis / Eczema
- Lichen planus
- Severe pruritus
- Vitiligo when it affects:
  - a. the skin of the head and/or neck area, or,
  - b. other body areas in excess of 30% of skin surface

4. UVB with the addition of topical coal tar (Goeckerman regimen) is considered medically necessary for severe psoriasis that affects 10% or more of the body.

5. Photodynamic therapy utilizing Levulan Kerastick and blue light, or Metvixia and red light is considered medically necessary for treatment of actinic keratoses after failure of topical therapy or cryotherapy with liquid nitrogen.

6. Photodynamic therapy is considered medically necessary for the treatment of superficial basal cell skin cancer, actinic keratoses, and cutaneous squamous cell carcinoma in situ (Bowen's disease) in accordance with NCCN guidelines.

7. Excimer laser phototherapy is considered medically necessary for the treatment of vitiligo which is not responsive to other forms of conservative therapy (e.g., topical corticosteroids, coal/tar preparations, and ultraviolet light).

**Home Light Therapy Units**

Home light therapy will be covered if all of the following criteria are met:

1. The panel is requested by a dermatologist; and
2. The individual is under the requesting provider's supervision with regularly scheduled exams (patient is seen at least once a year); and
3. Treatment is expected to be ongoing or long term (e.g., greater than 4 months) ; and
4. The individual has a diagnosis of one of the following:

- psoriasis characterized by  $\geq 5\%$  of body surface area involved or disease involving crucial body areas such as the hands, feet, face, or genitals, and a therapeutic failure on, intolerance to, or contraindication to topical therapy
  - atopic dermatitis / Eczema
  - Lichen planus;
  - Localized scleroderma
  - Chronic urticaria
  - Severe pruritus
  - Cutaneous T-cell lymphoma (e.g., mycosis fungoides)
  - Vitiligo when it affects:
    - a. the skin of the head and/or neck area, or,
    - b. other body areas in excess of 30% of skin surface
5. The panel size requested is appropriate for the affected area(s).

**EXCLUSIONS:**

Phototherapy as a first line of therapy for any dermatological condition is considered **not medically necessary**.

Home tanning beds for any use is **NOT COVERED**.

Phototherapy is considered COSMETIC when used to alter one's appearance, including but not limited to Vitiligo, Alopecia Areata, and therefore is **NOT COVERED**.

The Plan does **NOT** routinely provide coverage for Phototherapy as a treatment for other conditions not listed, including but is not limited to Granuloma Annulare and Photodermatoses, because it is considered **experimental, investigational or unproven**. There is insufficient evidence in the peer-reviewed published medical literature to establish the effectiveness of this treatment on health outcomes when compared to established treatments or technologies. Coverage of phototherapy in these circumstances will be considered only in exceptional cases. Determination of coverage will be considered on a case by case basis when there is no FDA-approved or standard of care, after thorough communication between the treating physician and the Plan.

**Note: A complete description of the process by which a given technology or service is evaluated and determined to be experimental, investigational or unproven is outlined in MP 15 - Experimental Investigational or Unproven Services or Treatment.**

**Medicaid Business Segment:**

Any requests for services, that do not meet criteria set in the PARP, may be evaluated on a case by case basis.

**CODING ASSOCIATED WITH:** Phototherapy for the Treatment of Dermatological Conditions

*The following codes are included below for informational purposes and may not be all inclusive. Inclusion of a procedure or device code(s) does not constitute or imply coverage nor does it imply or guarantee provider reimbursement. Coverage is determined by the member specific benefit plan document and any applicable laws regarding coverage of specific services. Please note that per Medicare coverage rules, only specific CPT/HCPCS Codes may be covered for the Medicare Business Segment. Please consult the CMS website at [www.cms.gov](http://www.cms.gov) or the local Medicare Administrative Carrier (MAC) for more information on Medicare coverage and coding requirements.*

- 0016M** Oncology (bladder), mRNA, microarray gene expression profiling of 219 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as molecular subtype (luminal, luminal infiltrated, basal, basal claudin-low, neuroendocrine-like) (Decipher)
- 96567** Photodynamic therapy by external application of light to destroy premalignant and/or malignant lesions of the skin and adjacent mucosal (Eg. lip) by activation of photosensitive drug(s), each phototherapy session.
- 96900** actinotherapy (ultraviolet light)
- 96910** Photochemotherapy; tar and ultraviolet B (Goeckerman treatment) or petrolatum and ultraviolet B
- 96912** Photochemotherapy; psoralens and ultraviolet A (PUVA)
- 96913** Photochemotherapy (Goeckerman and/or PUVA) for severe photoresponsive dermatoses requiring at least four to eight hours of care under direct supervision of the physician (includes application of medication and dressings) (when specified as PUVA)
- 96920** Laser treatment for inflammatory skin disease (psoriasis); total area less than 250 sq. cm
- 96921** Laser treatment for inflammatory skin disease (psoriasis); 250 sq. cm to 500 sq. cm

**96922** Laser treatment for inflammatory skin disease (psoriasis); over 500 sq. cm  
**A4633** Replacement bulb/lamp for ultraviolet light therapy system, each  
**E0691** Ultraviolet light therapy system panel, includes bulbs/lamps, timer, and eye protection; treatment area two square feet or less  
**E0692** Ultraviolet light therapy system panel, includes bulbs/lamps, timer, and eye protection, four foot panel  
**E0693** Ultraviolet light therapy system panel, includes bulbs/lamps, timer, and eye protection, six foot panel  
**E0694** Ultraviolet multidirectional light therapy system in 6 foot cabinet, includes bulbs/lamps, timer, and eye protection

Current Procedural Terminology (CPT®) © American Medical Association: Chicago, IL

#### **LINE OF BUSINESS:**

**Eligibility and contract specific benefits, limitations and/or exclusions will apply. Coverage statements found in the line of business specific benefit document will supersede this policy. For PA Medicaid Business segment, this policy applies as written.**

#### **REFERENCES:**

Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol 2010 Jan;62(1):114-35.

Gawkrodger DJ, Ormerod AD, Shaw L, et al. Therapy Guidelines and Audit Subcommittee, British Association of Dermatologists, Clinical Standards Department, Royal College of Physicians of London, Cochrane Skin Group, Vitiligo Society. Guideline for the diagnosis and management of vitiligo. Br J Dermatol 2008 Nov;159(5):1051-76

Yones SS, Palmer RA, Garibaldinos TM et al. Randomized double-blind trial for treatment of vitiligo. Arch Dermatol 2007; 143(5):578-84

Dayal S, Mayanka, Jain VK. Comparative evaluation of NBUVB phototherapy and PUVA photochemotherapy in chronic plaque psoriasis. Indian J Dermatol Venereol Leprol 2010;76:533-7

Sivanesan SP, Gattu S, et al. Randomized, double-blind, placebo-controlled evaluation of the efficacy of oral psoralen plus ultraviolet A for the treatment of plaque-type psoriasis using the Psoriasis Area Severity Index score (improvement of 75% or greater) at 12 weeks. J Am Acad Dermatol 2009; 61(5):793-8.

The known health effects of UV, World Health Organization, 2011, accessed on 11/2/11 at:  
<http://www.who.int/uv/faq/uvhealthfac/en/index1.html>

Kee Suck Suh, M.D., Jin Seuk Kang, M.D., et al. Efficacy of Ultraviolet A1 Phototherapy in Recalcitrant Skin Diseases, Ann Dermatol. 2010 February; 22(1): 1–8.

UpToDate, Treatment of chronic graft-versus-host disease, last updated: Apr 20, 2020

UpToDate, Treatment of advanced stage (IIB to IV) mycosis fungoides and Sézary syndrome, last updated: May 19, 2020

UpToDate, Evaluation and Management of severe refractory atopic dermatitis (eczema), last updated: Mar 18, 2021

UpToDate, Treatment of morphea (localized scleroderma) in adults, last updated: Jul 28

UpToDate, Management of alopecia areata, last updated: Mar 03, 2021

UpToDate, Photosensitive disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment, last updated: Mar 10, 2021.

UpToDate, UVA1 phototherapy. Last update Jan 08, 2021

UpToDate, Vitiligo. Last reviewed Oct 26, 2020

American Cancer Society, Getting Photodynamic Therapy. Last Revised: March 2, 2020  
<https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/radiation/photodynamic-therapy.html>

- Chern E, Yau D, et al. Positive effect of modified Goeckerman regimen on quality of life and psychosocial distress in moderate and severe psoriasis. *Acta Derm Venereol.* 2011 Jun;91(4):447-51
- Homan MWL, Spuls PI, de Korte P, et al. The burden of vitiligo; patient characteristics associated with quality of life. *J Am Acad Derm* 2009;61(3):411-420.
- Al-Mutairi N, Al-Haddad A. Targeted phototherapy using 308 nm Xecl monochromatic excimer laser for psoriasis at difficult to treat sites. *Lasers Med Sci.* 2012 Sep 28
- Mudigonda T, Dabade TS, West CE, Feldman SR. Therapeutic modalities for localized psoriasis: 308-nm UVB excimer laser versus nontargeted phototherapy. *Cutis.* 2012 Sep;90(3):149-54.
- Park KK, Swan J, Koo J. Effective treatment of etanercept and phototherapy-resistant psoriasis using the excimer laser. *Dermatol Online J.* 2012 Mar 15;18(3):2.
- Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. *J Am Acad Dermatol.* 2010 Jan;62(1):114-35.
- Le Duff F, Fontas E, Giacchero D, et al. 308-nm excimer lamp vs. 308-nm excimer laser for treating vitiligo: A randomized study. *Br J Dermatol.* 2010;163(1):188-192.
- Gawkrodger DJ, Ormerod AD, Shaw L, et al. Vitiligo: Concise evidence based guidelines on diagnosis and management. *Postgrad Med J.* 2010;86(1018):466-471
- American Academy of Dermatology (AAD). Psoriasis: Recommendations for UVB combination therapies. Practice Management Center. 2018.
- National Comprehensive Cancer Network (NCCN) Guidelines in Oncology. Squamous Cell Skin Cancer v1.2021
- National Comprehensive Cancer Network (NCCN) Guidelines in Oncology. Basal Cell Skin Cancer v2.2021
- Elmets CA, Lim HW, Stoff B, et al. Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. *J Am Acad Dermatol.* 2019; 81(3):775-804.
- Lovgren M-L, Scarisbrick JJ. Update on skin directed therapies in mycosis fungoides. *Chin Clin Oncol.* 2019;8(1):7.
- Phan K, Ramachandran V, Fassihi H, Sebaratnam DF. Comparison of narrowband UV-B with psoralen-UV-A phototherapy for patients with early-stage mycosis fungoides: A systematic review and meta-analysis. *JAMA Dermatol.* 2019;155(3):335-341.
- Yanovsky RL, Huang KP, Buzney EA. Optimizing narrowband UVB phototherapy regimens for psoriasis. *Dermatologic clinics.* 2020;38(1):1-10.
- Foerster J, Dawe R. Phototherapy achieves significant cost savings by the delay of drug-based treatment in psoriasis. *Photodermatology, photoimmunology & photomedicine.* 2020;36(2):90-96
- Jacob J, Pona A, Cline A, Feldman S. Home UV phototherapy. *Dermatol Clin.* 2020;38(1):109-126
- Chang HC, Sung CW. Efficacy of combination therapy of narrowband-ultraviolet B phototherapy or excimer laser with topical tacrolimus for vitiligo: An updated systematic review and meta-analysis. *Photodermatol Photoimmunol Photomed.* 2021;37(1):74-77
- Kim WI, Kim S, Lee SH, Cho MK. The efficacy of fractional carbon dioxide laser combined with narrow-band ultraviolet b phototherapy for non-segmental vitiligo: A systematic review and meta-analysis. *Lasers Med Sci.* 2021;36(1):165-173
- Musters AH, Mashayekhi S, Harvey J, et al. Phototherapy for atopic eczema. *Cochrane Database Syst Rev.* 2021;10:Cd013870

This policy will be revised as necessary and reviewed no less than annually.

**Devised:** 11/21/2011

**Revised:** 3/12, 3/13 (added indication), 3/15 (added indication); 6/15 (add criteria for home light units); 4/17 (revise home UVB criteria) 7/17 (expand home criteria); 4/18 (expand criteria); 4/21 (expand PUVA indications), 4/22 (Remove P/A)

**Reviewed:** 3/14; 5/16, 4/19, 4/20, 4/23

Geisinger Health Plan may refer collectively to health care coverage sponsors Geisinger Health Plan, Geisinger Quality Options, Inc., and Geisinger Indemnity Insurance Company, unless otherwise noted. Geisinger Health Plan is part of Geisinger, an integrated health care delivery and coverage organization.

Coverage for experimental or investigational treatments, services and procedures is specifically excluded under the member's certificate with Geisinger Health Plan. Unproven services outside of an approved clinical trial are also specifically excluded under the member's certificate with Geisinger Health Plan. This policy does not expand coverage to services or items specifically excluded from coverage in the member's certificate with Geisinger Health Plan. Additional information can be found in MP015 Experimental, Investigational or Unproven Services.

Prior authorization and/or pre-certification requirements for services or items may apply. Pre-certification lists may be found in the member's contract specific benefit document. Prior authorization requirements can be found at <https://www.geisinger.org/health-plan/providers/ghp-clinical-policies>

Please be advised that the use of the logos, service marks or names of Geisinger Health Plan, Geisinger Quality Options, Inc. and Geisinger Indemnity Insurance Company on a marketing, press releases or any communication piece regarding the contents of this medical policy is strictly prohibited without the prior written consent of Geisinger Health Plan. Additionally, the above medical policy does not confer any endorsement by Geisinger Health Plan, Geisinger Quality Options, Inc. and Geisinger Indemnity Insurance Company regarding the medical service, medical device or medical lab test described under this medical policy.